

378

POSTER

Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. Protocol AGO-GYN 5, AGO Study Group, Germany

G. Emons¹, J. Sehouli², G. Gorchev³, A. Hristamian⁴, A. Staehle⁵, L.C. Hanker⁶, P. Wimberger⁷, M.W. Beckmann⁸, V. Taskova⁹, C. Gruendker¹. ¹University of Göttingen, Department of Obstetrics & Gynecology, Goettingen, Germany; ²Charité Clinic, Department of Obstetrics & Gynecology, Berlin, Germany; ³University Hospital Pleven, Department of Obstetrics & Gynecology, Pleven, Bulgaria; ⁴Regional Oncodispensary Plovdiv, Department of Obstetrics & Gynecology, Plovdiv, Bulgaria; ⁵Vincent Hospital, Department of Obstetrics & Gynecology, Karlsruhe, Germany; ⁶Clinic of Goethe University, Department of Obstetrics & Gynecology, Frankfurt am Main, Germany; ⁷University Hospital, Department of Obstetrics & Gynecology, Essen, Germany; ⁸University Erlangen, Clinic for Gynecology, Erlangen, Germany; ⁹Regional Oncodispensary Varna, Department of Obstetrics & Gynecology, Varna, Bulgaria

Background: Gynecological cancers commonly express receptors for luteinizing hormone releasing hormone (LHRH-R). AEZS-108 (AN-152) is a targeted cytotoxic drug in which doxorubicin is linked to [D-Lys(6)]-LHRH. A phase I study in patients (pts) with LHRH-R positive tumors recommended a dose of 267 mg/m² by 2-hour intravenous infusion in 3-week cycles. We aimed to assess the efficacy and tolerability of AEZS-108 in endometrial cancer.

Material and Methods: Pts with histologically confirmed LHRH-R positive advanced (FIGO III or IV) or recurrent endometrial cancer received AEZS-108 for a planned duration of 6 treatment courses. At least 1 measurable lesion was required at baseline. An independent radiologic review was performed. Response rate per RECIST was defined as primary endpoint. Secondary endpoints were safety, time-to-progression (TTP) and overall survival (OS).

Results: In all, 43 pts with a median age of 68 years (range 25–88) entered the study. Tumors of all patients were confirmed as LHRH-R positive; percentages of tumor cells staining for LHRH-R ranged 30% to 90% (median 70%). 27 pts had primary diagnosis of EC FIGO III/IV. Majority of tumors with endometrioid (31 pts) or serous (8 pts) histology. Prior treatment included surgery (42 pts), radiotherapy (29 pts), chemotherapy (9 pts) and hormonal therapy (11 pts). 28 pts (62.8%) received AEZS-108 for 6 courses (2 pts with 8 courses), only one pt was retreated at a reduced dose. Possibly drug related adverse events, except for hematologic toxicity Grade 3/4 (rapidly reversible neutropenia: 60%, anemia: 5%), was commonly limited to CTCAE grade 1/2. There was 1 pt each with febrile neutropenia and a Grade 2 hand-foot-syndrome. There was no evidence of cardiotoxicity in serial controls of LVEF. Only one pt stopped therapy for toxicity (recurrent anemia). Serial measurements of LH and FSH showed partial suppression (median 25–50%). Independent review, which is currently ongoing, has confirmed the target minimum of 5 responses. Definite results for further reported responses with preliminary judgement as 4 CR, 10 PR and – at end of course 6 – 15 SD are expected.

Conclusions: AEZS-108 was well tolerated in pts with endometrial cancer and confirmed the recommended dose of 267 mg/m². Therapeutic activity exceeded the minimum response rate for continuing development. Follow-up is ongoing to define TTP and survival.

The trial was supported by Aeterna Zentaris, Frankfurt, Germany.

379

POSTER

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients (pts) with advanced solid tumors, non-Hodgkin's lymphomas (NHL) and multiple myeloma (MM)

C. Sessa¹, G. Martinelli², D. Hess³, A. Delmonte⁴, C. Noberasco⁴, S. Sammassino², E. Gallerani¹, S. Marsoni⁵, G. Camboni⁶, F. de Braud⁴. ¹IOSI – San Giovanni Hospital, Department of Medical Oncology, Bellinzona, Switzerland; ²IEO – Istituto Europeo di Oncologia, Division of Haemato-Oncology, Milan, Italy; ³KSSG – Kantonsspital St. Gallen, Oncology/Hematology department, St Gallen, Switzerland; ⁴IEO – Istituto Europeo di Oncologia, Department of Clinical Pharmacology and New Drugs, Milan, Italy; ⁵SENDO – Southern Europe New Drug Organization, General Director, Milan, Italy; ⁶EOS – Ethic Oncology Science, Chief Operating Officer, Milan, Italy

Background: CEP-18770 (CEP) is a new boronic acid inhibitor of mammalian proteasome. Preclinical data showed antitumor activity in a wide range of solid and haematological malignancies. Aim of this multicentric study was to determine the CEP maximum tolerated dose (MTD) and its pharmacokinetic (PK) and proteasome inhibition (PD) profile, in pts with advanced solid tumors, NHL and MM.

Methods: Treatment consisted of D1, 4, 8, 11 i.v. administration Q21D for 6 cycles (cys), unless progression or toxicity. A modified accelerated dose titration design (2 cohorts) and a 3 + 3 dose-escalation design were followed. MTD was 1 level below the dose at which ≥2/6 pts experienced dose limiting toxicity (DLT) in the 1st cy. Eligible pts received ≤3 previous chemotherapies for advanced disease and ≤5 in case of MM. Adverse Events (AEs) were graded by the NCI CTCAE. Tumor response was assessed every 2 cys. PK and proteasome inhibition were evaluated on blood collected on cy 1.

Results: Thirty-one solid tumours and 7 MM were treated. Pts characteristics: median age 60 yrs (35–74), ECOG PS 0/1 39.5/60.5%, 34% received ≥2 lines prior therapy for metastatic disease and 42.9% of MM pts received bortezomib. Pts received a median of 2 cys (1–7). Eight dose levels were explored from 0.1 up to 1.8 mg/m²; at MTD (1.5 mg/m²) 16 pts were treated (7 MM). Three pts experienced DLTs: 1 at level 0.6 mg/m² (diarrhea G3) and 2 at level 1.8 mg/m² (the Maximum Administered Dose) respectively rash G3 in one pt and diarrhea/vomiting/anorexia/asthenia G3 in the other one. More frequent G1-G3 AEs were cutaneous (rash 50%, pruritus 10.5% and erythema 5.3%). Other common AEs, were asthenia (23.7%), stomatitis (21.1%), nausea and diarrhea (18.4%), anorexia (13.2%). Three possibly drug related Serious AEs were reported: asthenia, acute renal failure and pneumonia. Neurological effects were limited: 1 pt had paresthesia G2 and neuralgia G3, other 4 pts experienced neurotoxicity G1 without any evidence of cumulative toxicity. One pt experienced atrial fibrillation and palpitation G3. Two objective responses were recorded in MM pts both not previously treated with bortezomib; disease stabilization was reported in 15 pts (27%) for a median time of 4 mos. (2.8–6.1).

CEP showed a linear PK with about 50% inhibition of proteasome activity at the MTD (1.5 mg/m²).

Conclusion: When administered on days 1, 4, 8, and 11 of a 21 day cycle, the MTD of CEP-18770 is 1.5 mg/m². The promising activity of CEP in 2 of 7 MM pts justifies further testing also in combination.

380

POSTER

Phase I trial of OXi4503: positron emission tomography (PET) analysis shows early effects on tumour perfusion that predict metabolic response

P. Price¹, M.C. Asselin², B. Kotz³, N. Charnley³, G. Watkins³, G.J.S. Rustin⁴, J. Balkissoon⁵, Z. Goldberg⁵, C. Drug Development Office⁶, A. Saleem³. ¹Imperial College, Surgery and Oncology, London, United Kingdom; ²University of Manchester, Wolfson Molecular Imaging Centre, Manchester, United Kingdom; ³University of Manchester, Academic Radiation Oncology, Manchester, United Kingdom; ⁴Mount Vernon Cancer Centre, Medical Oncology (Director), London, United Kingdom; ⁵OXiGENE Inc., Oncology, South San Francisco, USA; ⁶London Research Institute, Cancer Research UK, London, United Kingdom

Background: OXi4503 (OXiGENE Inc.) is the diphosphate pro-drug of combretastatin A1, a second-generation tubulin-binding vascular disruptive agent (VDA). As part of a phase I trial (Zweifel et al., ASCO Proceedings 2010), we used positron emission tomography (PET) analysis to assess the anti-vascular and metabolic effects of OXi4503 in normal and metastatic regions of interest (ROI; n=28) in seven patients with advanced solid tumours.

Materials and Methods: [¹⁵O]-H₂O and [¹⁸F]-fluorodeoxyglucose (FDG) scans were performed before (baseline) and after (90 mins, 24 hrs and 28 days) administration of OXi4503 (1.92–15.4 mg/m²) on days 1, 8 and 15 (1 cycle). FDG standardized uptake value (SUV) was semi-quantitatively derived to assess metabolic changes. The rate of tumour/tissue blood flow (TBF) and the volume of distribution (Vt; the partition co-efficient) were derived from compartmental blood flow modelling of [¹⁵O]-H₂O scan data to assess perfusion.

Results: Analysis in all metastases showed mean TBF decreased by 22.8% at 24 hrs post-infusion compared with baseline measurements (p = 0.006). Mean Vt decreased by 6.5% at 90 mins (p = 0.025) and 6% at 24 hrs (p = 0.028). Mean changes per patient are shown in Figs 1A+B. No significant changes were observed in normal tissues, showing a specificity of OXi4503 for tumour. Excluding one patient who showed rapid clinical progression, mean FDG decreased by 15% at 28 days (p = 0.015; Fig 1C), demonstrating inhibition of tumour growth in 6/7 patients. The % change in TBF at 24 hrs correlated significantly with % change in FDG at 28 days (p = 0.022; Fig 1D), indicating a predictive relationship between early mechanistic drug action and tumour response. When compared with an earlier PET study of combretastatin A4 phosphate (CA4P; Anderson et al., JCO 2003), similar acute changes were observed for TBF and cardiac output reductions. However, OXi4503 induced a greater reduction in mean TBF at 24 hrs compared with CA4P (22.8% vs 2%, respectively; p = 0.019), suggesting a more sustained effect. Different acute effects were also observed on normal kidney blood flow, with a reduction of 6.2% with

CA4P at 30 mins and an increase of 15.6% with OXi4503 at 90 mins ($p=0.012$), indicating potential advantage for combination therapy.

Conclusions: PET provided evidence of early anti-vascular mechanistic effects and anti-proliferative response following 1 cycle of OXi4503, even at low doses, and in a range of tumour types (now in phase 1b trial). Early changes in PET derived tumour perfusion may be useful bio-indicators of tumour response for VDAs.




Figure 1.

381 POSTER Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) "trap" FP-1039 (FGFR1:Fc) in patients with advanced malignancies

A. Tolcher¹, K. Papadopoulos¹, A. Patniak¹, E. Heath², A. Weise², T. Prokop², S. Morrone³, J. Zanghi⁴, H.N. Keer², P. LoRusso².
¹START, Clinical Trials, San Antonio, USA; ²Karmanos Cancer Institute, Developmental Therapeutics, Detroit MI, USA; ³Five Prime Therapeutics, Clinical Development, San Francisco CA, USA; ⁴Five Prime Therapeutics, Preclinical Development, San Francisco CA, USA

Background: The human FGF axis has been implicated in tumor growth promotion, angiogenesis, and tumor stem cell maintenance. FP-1039 acts as a ligand "trap" that sequesters multiple FGF family ligands, neutralizing their ability to bind to and activate multiple FGF receptors. FP-1039 targets multiple FGFs linked to multiple cancers, but does not target members of the keratinocyte growth factor subfamily (FGF-7, -10, -22: ligands of the putative tumor suppressor, FGFR2b) or the hormonal FGFs (FGF-19, -21, -23, involved in bile acid, glucose and phosphate regulation, respectively). FP-1039 has anti-tumor activity in multiple xenograft models, both as a single agent and in combination with other anticancer agents. We report preliminary results of a first-in-human study of FP-1039 as a single agent in patients with advanced solid malignancies.

Methods: Subjects received 4 once-weekly iv doses of FP-1039 by 30 min infusion, followed by a 2 week observation period. In the absence of unacceptable toxicity or progressive disease, patients were eligible to receive additional weekly doses of FP-1039. Plasma samples were taken for PK, pharmacodynamic biomarker, and immunogenicity studies.

Results: 24 subjects have received FP-1039 at doses from 0.5–4.0 mg/kg. While 2 DLTs were observed in the initial 1 mg/kg dosing cohort, no consistent pattern related to drug exposure could be discerned and confounding factors were present. Therefore, dose escalation continued beyond 1 mg/kg, and FP-1039 has been well tolerated to date without observations of drug-related weight loss, hypertension, or soft tissue calcification. PK analysis revealed a linear, dose-dependent increase in drug exposure in the plasma compartment. Mean terminal half-lives ranged from 63 to 102 hours, and appeared to be similar on Day 1 and Day 22. There was accumulation after 4 weekly doses of FP-1039. Free plasma FGF2 levels were assessed prior to initial dosing and at subsequent timepoints. All subjects had elevated FGF2 levels prior to FP-1039 treatment compared to normal individuals, and a decrease in free FGF2 following FP-1039 treatment. 15 subjects completed the treatment period, 7 did not due to adverse events or rapidly progressive disease, and 2 are pending. By RECIST criteria, 8 subjects had stable disease. In a subject with progressive prostate cancer after castration and docetaxel, a reduction in FDG PET SUV on 2- and 6-week scans and a 20% decrease in tumor size by CT scan were demonstrated.

Conclusions: FP-1039 appears to be well tolerated at doses of 0.5–4 mg/kg, and exploration of higher doses is in progress. Preliminary PK and target engagement data (reduction in FGF2) support a weekly or longer dosing interval. The adverse event profile observed to date suggests FP-1039 may be incorporated into multi-drug regimens containing chemotherapy and/or biologic therapies. Preliminary single agent activity is promising. These data suggest that phase 1b combination studies and a phase II single agent study of FP-1039 are warranted.

382 POSTER Influence of rosuvastatin on the pharmacokinetics of imatinib: a cross-over study


K. Eechoute¹, R.M. Franke², W.J. Loos¹, P. de Bruijn¹, J. Verweij¹, A. Sparreboom², R.H.J. Mathijssen¹. ¹Erasmus University Medical Center, Medical Oncology, Rotterdam, The Netherlands; ²St. Jude Children's Research Hospital, Pharmaceutical Sciences, Memphis, USA

Background: The oral bioavailability of imatinib (Gleevec®) is about 90–95%. We previously reported that imatinib is a substrate of the intestinal uptake transporter, OATP1A2 (SLCO1A2) (Hu et al, *Clin Cancer Res* 2008). We hypothesized that the absorption of imatinib may be reduced by medication that blocks OATP1A2 function, such as rosuvastatin (Crestor®), a frequently used HMG-CoA reductase inhibitor in Europe.

Material and Methods: Serial blood samples were obtained from 12 patients with gastrointestinal stromal tumors (11 male, 1 female; age, 38–70 years old) receiving imatinib monotherapy (400 mg per day) before and after concomitant dosing of rosuvastatin for 14 days (20 mg a day; intake 20 min prior to imatinib). Plasma concentrations of imatinib and its active metabolite CGP74588 were determined by LC-MS/MS. Pharmacokinetic (PK) parameters were estimated by non-compartmental analysis using WinNonLin.

Results: The systemic exposure (AUC) to imatinib and CGP74588 did not differ between the first and second PK-measurement (37.6 v 37.0 and 7.18 v 6.62 µg × h/mL, respectively), as shown in Figure 1. There was a trend ($P=.065$; paired t-test) towards a lower AUC ratio of CGP74588/imatinib during rosuvastatin co-treatment (0.197 v 0.187), suggesting a lower metabolic conversion and/or an altered hepatobiliary excretion. In general, treatment-related toxicity did not alter as a result of rosuvastatin co-administration, except for grade 2 edema and diarrhea in 1 patient, and grade 1 muscle cramps in 2 patients.

Conclusion: The combination of imatinib and rosuvastatin does not lead to a substantially reduced systemic exposure to the anti-cancer drug at steady-state, suggesting that the intestinal absorption of imatinib is unaltered. Although rosuvastatin may inhibit formation of the active metabolite CGP74588, this is unlikely to have a negative influence on anti-cancer activity.



383 POSTER First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics

C.D. Britten¹, A.A. Adjei², R. Millham³, B. Houk⁴, Z.A. Wainberg¹, T. Guthrie⁵, G. Dy², P.M. LoRusso⁵. ¹David Geffen School of Medicine at UCLA, Medicine, Los Angeles, USA; ²Roswell Park Cancer Institute, Medicine, Buffalo, USA; ³Pfizer Oncology, Clinical Development and Medical Affairs, New London, USA; ⁴Pfizer Oncology, Clinical Development and Medical Affairs, La Jolla, USA; ⁵Karmanos Cancer Institute, Medical Oncology, Detroit, USA

Background: The PI3K/mTOR pathway regulates cell growth, proliferation, glucose metabolism and survival. The significance of the pathway has